Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial
暂无分享，去创建一个
E. Silverman | A. Martini | R. Burgos-Vargas | C. Duarte | R. Xavier | H. Brunner | D. Lovell | F. De Benedetti | I. Calvo Penadés | V. Keltsev | N. Ruperto | C. Job-Deslandre | Z. Żuber | Y. Kimura | G. Espada | W. Douglass | R. Joos | R. Cuttica | C. Wells | S. Wimalasundera | K. Bharucha | Manuel Ferrandiz Zavaler